{
  "id": "5c900983ecadf2e73f000002",
  "type": "list",
  "question": "Name siRNA drugs that have entered phase 2-3 clinical trials (by 2019).",
  "ideal_answer": "siRNAs that have entered phase 2-3 clinical trials by 2019 include PF-04523655, TKM-080301, Atu027, SYL040012, SYL1001, siG12D-LODER (phase 2), QPI-1002, QPI-1007, and patisiran (phase 3).",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/28389707"
  ],
  "snippets": [
    {
      "text": " This review addresses nine small-interfering RNAs (siRNAs) and one unique microRNA (miRNA) inhibitor, which entered the phase 2-3 clinical trials. The siRNAs in focus are PF-04523655, TKM-080301, Atu027, SYL040012, SYL1001, siG12D-LODER (phase 2), QPI-1002, QPI-1007, and patisiran (phase 3). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28389707",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "PF-04523655, TKM-080301, Atu027, SYL040012, SYL1001, siG12D-LODER, QPI-1002, QPI-1007, patisiran"
}